Cyclo Therapeutics, Inc.

Quick facts

Phase 3 pipeline

• Hydroxypropyl-beta-cyclodextrin · Rare Genetic Disorders / Lysosomal Storage Diseases
  Hydroxypropyl-beta-cyclodextrin is a solubilizing excipient that forms inclusion complexes with lipophilic drugs to improve their bioavailability and enable intravenous delivery.

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Cyclo Therapeutics, Inc. portfolio CI brief
• Cyclo Therapeutics, Inc. pipeline updates RSS